Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri
Michelle A
MA
Johns Hopkins University Medical Center, Baltimore, Maryland 21205, USA. mpetri@welch.jhu.edu
Mease
Philip J
PJ
Merrill
Joan T
JT
Lahita
Robert G
RG
Iannini
Mark J
MJ
Yocum
David E
DE
Ginzler
Ellen M
EM
Katz
Robert S
RS
Gluck
Oscar S
OS
Genovese
Mark C
MC
Van Vollenhoven
Ronald
R
Kalunian
Kenneth C
KC
Manzi
Susan
S
Greenwald
Maria W
MW
Buyon
Jill P
JP
Olsen
Nancy J
NJ
Schiff
Michael H
MH
Kavanaugh
Arthur F
AF
Caldwell
Jacques R
JR
Ramsey-Goldman
Rosalind
R
St  Clair
E William
EW
Goldman
Allan L
AL
Egan
Rita M
RM
Polisson
Richard P
RP
Moder
Kevin G
KG
Rothfield
Naomi F
NF
Spencer
Robert T
RT
Hobbs
Kathryn
K
Fessler
Barri J
BJ
Calabrese
Leonard H
LH
Moreland
Larry W
LW
Cohen
Stanley B
SB
Quarles
Betty J
BJ
Strand
Vibeke
V
Gurwith
Marc
M
Schwartz
Kenneth E
KE
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D003687:Dehydroepiandrosterone / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D011446:Prospective Studies; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D003687:Dehydroepiandrosterone